C
The startup develops multispecific antibodies that enhance the functionality of innate and adaptive immune cells, providing targeted engagement for improved therapeutic outcomes. This approach addresses the limitations of existing therapies by offering a more effective means to direct immune responses against diseases.
London, United Kingdom
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops multispecific antibodies that enhance the functionality of innate and adaptive immune cells, providing targeted engagement for improved therapeutic outcomes. This approach addresses the limitations of existing therapies by offering a more effective means to direct immune responses against diseases.